270 related articles for article (PubMed ID: 25291725)
1. Suvorexant: a novel therapy for the treatment of insomnia.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
[TBL] [Abstract][Full Text] [Related]
2. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
3. Suvorexant: something new for sleep?
Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.
Michelson D; Snyder E; Paradis E; Chengan-Liu M; Snavely DB; Hutzelmann J; Walsh JK; Krystal AD; Benca RM; Cohn M; Lines C; Roth T; Herring WJ
Lancet Neurol; 2014 May; 13(5):461-71. PubMed ID: 24680372
[TBL] [Abstract][Full Text] [Related]
5. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.
Herring WJ; Snyder E; Budd K; Hutzelmann J; Snavely D; Liu K; Lines C; Roth T; Michelson D
Neurology; 2012 Dec; 79(23):2265-74. PubMed ID: 23197752
[TBL] [Abstract][Full Text] [Related]
6. Suvorexant for the treatment of insomnia.
Jacobson LH; Callander GE; Hoyer D
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
8. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
9. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
Owen RT
Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
[TBL] [Abstract][Full Text] [Related]
10. Profile of suvorexant in the management of insomnia.
Sutton EL
Drug Des Devel Ther; 2015; 9():6035-42. PubMed ID: 26648692
[TBL] [Abstract][Full Text] [Related]
11. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
Patel KV; Aspesi AV; Evoy KE
Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
[TBL] [Abstract][Full Text] [Related]
12. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
[TBL] [Abstract][Full Text] [Related]
13. Suvorexant: first global approval.
Yang LP
Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
[TBL] [Abstract][Full Text] [Related]
14. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
J Clin Sleep Med; 2016 Sep; 12(9):1215-25. PubMed ID: 27397664
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of action of suvorexant.
Stahl SM
CNS Spectr; 2016 Jun; 21(3):215-8. PubMed ID: 27322687
[TBL] [Abstract][Full Text] [Related]
17. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
Kuriyama A; Tabata H
Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
[TBL] [Abstract][Full Text] [Related]
18. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Psychopharmacology (Berl); 2017 Jun; 234(11):1703-1711. PubMed ID: 28265715
[TBL] [Abstract][Full Text] [Related]
19. Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Snyder E; Snavely DB; Zhang Y; Hutzelmann J; Matzura-Wolfe D; Benca RM; Krystal AD; Walsh JK; Lines C; Roth T; Michelson D
Am J Geriatr Psychiatry; 2017 Jul; 25(7):791-802. PubMed ID: 28427826
[TBL] [Abstract][Full Text] [Related]
20. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
